Propanc Biopharma Inc. has announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy.
Substituted fluorinated N-propyl-pyrrolidine and n-propyl-azetidine compounds acting as estrogen receptor (ER) antagonists and selective estrogen receptor degradation (SERD) inducers have been reported in a Sanofi SA patent.
Merck KGaA scientists have identified new pyrido[3,2-d]pyrimidines acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors.
Myeloid cells expressing LILRB2 are abundant in the tumor microenvironment and can both drive cancer progression and hinder immune responses. Thus, targeting LILRB2 offers a potential strategy to boost immune-based cancer therapies, as it counteracts their suppressive effects on pro-inflammatory pathways.
Evotec SE and Dewpoint Therapeutics Inc. have established a strategic R&D collaboration to advance Dewpoint’s oncology pipeline programs of condensate modifying therapeutics to IND application stage.
RSS
